# Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients

> **NCT05155592** · PHASE2 · UNKNOWN · sponsor: **Dan Liang** · enrollment: 28 (estimated)

## Conditions studied

- Uveitis
- Adalimumab

## Interventions

- **BIOLOGICAL:** reduction or discontinuation of Adalimumab

## Key facts

- **NCT ID:** NCT05155592
- **Lead sponsor:** Dan Liang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-04-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2021-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155592, "Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05155592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*